This week, the ratings of three Pharmaceutical stocks on Portfolio Grader are down. Each of these rates a “D” (“sell”) or “F” overall (“strong sell”).

Impax Laboratories (NASDAQ:IPXL) is on the decline this week, earning a D (“sell”) after receiving a C (“hold”) last week. Impax Laboratories develops, manufactures, and markets both proprietary and multi-source pharmaceutical products utilizing its drug delivery technologies. The stock price has dropped 8.2% over the past month, worse than the 1.9% increase the Nasdaq has seen over the same period of time. To get an in-depth look at IPXL, get Portfolio Grader’s complete analysis of IPXL stock.

Salix Pharmaceuticals (NASDAQ:SLXP) experiences a ratings drop this week, going from last week’s C to a D. Salix Pharmaceuticals acquires, develops and commercializes prescription drugs used to treat gastrointestinal diseases. The stock has a trailing PE Ratio of 37.40. For more information, get Portfolio Grader’s complete analysis of SLXP stock.

Sucampo Pharmaceuticals’ (NASDAQ:SCMP) rating weakens this week, dropping to a D versus last week’s C. Sucampo Pharmaceuticals is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary drugs based on prostones, a class of compounds derived from functional fatty acids that occur naturally in the human body. The stock gets F’s in Earnings Revisions and Equity. For a full analysis of SCMP stock, visit Portfolio Grader.

Louis Navellier’s proprietary Portfolio Grader stock ranking system assesses roughly 5,000 companies every week based on a number of fundamental and quantitative measures. Stocks are given a letter grade based on their results — with A being “strong buy,” and F being “strong sell.” Explore the tool here.